Spider Versus Emboshield Distal Protection on Cerebral Microembolization During Vulnerable Plaque in Carotid Artery Stenting

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 172 participants.

Also called NCT04904250

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 172 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04904250
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04904250. Randomized; single masking; primary purpose treatment. Start 2022-08-27 (anticipated); primary completion 2024-05-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Spider Versus Emboshield Distal Protection on Cerebral Microembolization During Vulnerable Plaque in Carotid Artery Stenting
Acronym
CASH-ES
Condition
Stroke
Condition
Carotid Stenosis
Condition
Carotid Artery Stent
Intervention (Device)
Emboshield
Intervention (Device)
Spider
Lead sponsor
Xuanwu Hospital, Beijing (class: other)

Record details

Record id
cardio:ct-nct04904250
Content hash
62bd774c7ffcfdd7f1d8f2c48b5e1598f3c4f25cb20506ad825bdae3545becb2